Case Report
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 26, 2019; 7(14): 1899-1907
Published online Jul 26, 2019. doi: 10.12998/wjcc.v7.i14.1899
Multiline treatment of advanced squamous cell carcinoma of the lung: A case report and review of the literature
Xin Yang, Ping Peng, Li Zhang
Xin Yang, Ping Peng, Li Zhang, Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Author contributions: Zhang L performed the investigation and provided resources for the case care and report; Yang X and Peng P provided resources for the case report; Yang X wrote the first draft of the article; Peng P and Zhang L reviewed and edited the article for important intellectual content.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Institutional review board statement: The study protocol was approved by the Ethical Committee of Tongji Hospital.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Li Zhang, MD, PhD, Associate Professor, Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan 430030, Hubei Province, China. lizhang@tjh.tjmu.edu.cn
Telephone: +86-27-83663631 Fax: +86-27-83663631
Received: March 25, 2019
Peer-review started: March 26, 2019
First decision: April 18, 2019
Revised: May 10, 2019
Accepted: May 23, 2019
Article in press: May 23, 2019
Published online: July 26, 2019
Processing time: 125 Days and 19.2 Hours
Core Tip

Core tip: Patients with advanced squamous cell carcinoma (SCC) have a poor prognosis and their treatment options are limited. Nab-paclitaxel has a superior antitumor effect and plays a significant role in the treatment of advanced non-small cell lung cancer, especially SCC; radiotherapy, anaplastic lymphoma kinase-targeted therapy, and antiangiogenic therapy also make a great contribution to the patients’ survival. We should attach importance to multiline therapy and be flexible in our choice of the most suitable therapy method for those patients with SCC, including advanced cases.